P217: Overcoming Population Constraints: Regulatory-Led Digital Recruitment Innovation
Poster Presenter
Po-Hung Lee
Associate Reviewer
Taiwan's Food and Drug Administration (TFDA) Taiwan
Objectives
To examine how Taiwan FDA-led digital platform Light2Health tackles population-based clinical trial recruitment barriers through public-private partnership, offering a replicable framework for small-to-medium sized regulatory markets worldwide.
Method
TFDA commissioned TRPMA to build Light2Health, Asia's first government-guided clinical research intent registration platform. It enables centralized digital matching between patients and IRB-approved trials, shifting recruitment from passive to proactive participant-trial pairing.
Results
Light2Health created a centralized digital infrastructure linking patients, pharmaceutical companies, and research institutions through automated matching of potential participants with eligible clinical research opportunities.
Platform Architecture: The system pairs IRB-approved study registrations with patient intent profiles, enabling compliant participant-trial matching at national scale. This marks a departure from conventional site-based passive recruitment toward structured digital outreach.
Triple-Benefit Model: The win-win-win framework delivered tangible value to three stakeholder groups:
(1) Patient Access: Patients gained new pathways to discover and connect with innovative treatment opportunities that remained largely invisible under conventional recruitment channels.
(2) Industry Efficiency: Sponsors experienced streamlined recruitment workflows, reducing time-to-enrollment barriers that disproportionately affect small-population markets of 23 million residents.
(3) Healthcare System Optimization: Centralized coordination reduced duplicative recruitment efforts across institutions, improving resource utilization within Taiwan's clinical trial ecosystem.
Public-Private Partnership: The TFDA-TRPMA collaboration showed that regulatory leadership, paired with industry association execution, can bridge the gap between government oversight requirements and operational recruitment needs. This governance structure preserved regulatory compliance while enabling platform deployment at commercial scale.
Population Constraint Mitigation: Taiwan's experience confirmed that digital recruitment innovation can meaningfully offset inherent population limitations, strengthening competitiveness in global multi-regional clinical trials despite demographic constraints.
Conclusion
Light2Health shows that regulatory-led digital innovation can substantively address population-based recruitment challenges in clinical trial operations. By commissioning industry partners to build national recruitment infrastructure, TFDA established a governance model where regulators function not solely as oversight bodies but as catalysts for operational improvement.
Three implications stand out:
Replicability for small-medium markets. Countries facing comparable population constraints can adapt the public-private partnership framework and centralized digital matching approach to their own regulatory environments. The model holds particular relevance for markets across Southeast Asia, Scandinavia, and other regions where population size restricts conventional recruitment.
Regulatory role expansion. TFDA's initiative represents a broadened regulatory function that extends beyond approval and supervision into active facilitation of clinical trial ecosystem development, positioning the authority as a strategic enabler of patient access to innovative treatments.
Sustainability of recruitment infrastructure. The platform architecture supports long-term operation beyond individual trial cycles, building persistent national capacity for clinical research participant engagement. This converts recruitment from a per-trial cost center into a shared public resource.
Taiwan's validated win-win-win framework offers a practical blueprint for regulators, industry, and healthcare systems aiming to strengthen clinical trial recruitment under population constraints while upholding rigorous regulatory standards.
